首页> 外文期刊>European review for medical and pharmacological sciences. >The efficacy and tolerability of Streptococcus salivarius 24SMB and Streptococcus oralis 89a administered as nasal spray in the treatment of recurrent upper respiratory tract infections in children
【24h】

The efficacy and tolerability of Streptococcus salivarius 24SMB and Streptococcus oralis 89a administered as nasal spray in the treatment of recurrent upper respiratory tract infections in children

机译:唾液链球菌24SMB和口腔链球菌89a鼻喷剂治疗儿童反复上呼吸道感染的疗效和耐受性

获取原文
           

摘要

OBJECTIVE: Nasal administration of Streptococcus salivarius 24SMB and Streptococcus oralis 89a has been proposed to reduce the risk of new episodes of adenoiditis, tonsillitis and acute rhinosinusitis in children. PATIENTS AND METHODS: We enrolled 202 children with a recent diagnosis of recurrent upper respiratory tract infection. All the patients were treated twice daily for 7 days each month for 3 consecutive months with a nasal spray whose active agents were two specific bacterial strains: Streptococcus salivarius 24SMB and Streptococcus oralis 89a. Evaluation was performed at the end of treatment and at follow-up at 3, 6, and 12 months. RESULTS: Patients who completed the entire 90-day course of bacteriotherapy and the follow-up period showed a 64.3% reduction in their episodes of upper respiratory tract infections compared to the number of episodes recorded in the previous year. Treatment decreased the reported incidence of infection events by 52.4% in the first 3 months, 31.2% at 6-month follow-up, and 20.8% after 12 months. Enrolled patients tolerated the product well, and there were no dropouts. CONCLUSIONS: Prophylactic bacteriotherapy by administration of Streptococcus salivarius 24SMB and Streptococcus oralis 89a in children with a history of recurrent upper respiratory tract infection could reduce the number of episodes of otolaryngologic infections. Bacteriotherapy can be even more clinically important due to increasing difficulty in finding new effective antibiotic compounds. New alternative therapeutic approaches must be found with, in comparison to antibiotics, greater specificity and safety with respect to patients’ native beneficial flora; lack of drug interactions; the ability to leverage complementary systemic modes of action; and drastically reduced risk of developing resistance within the patient population and the environment.
机译:目的:建议口服唾液链球菌24SMB和口腔链球菌89a可降低儿童新发腺样炎,扁桃体炎和急性鼻-鼻窦炎的风险。患者与方法:我们招募了202例最近诊断为复发性上呼吸道感染的儿童。所有患者均每天两次连续7个月每月两次,连续7个月接受鼻喷剂治疗,鼻喷剂的活性剂为两种特定的细菌菌株:唾液链球菌24SMB和口腔链球菌89a。在治疗结束时以及在3、6和12个月的随访中进行评估。结果:完成了整个90天细菌治疗过程和随访期的患者与上一年记录的发作次数相比,上呼吸道感染发作次数减少了64.3%。治疗使报告的感染事件发生率在前三个月降低了52.4%,在六个月的随访中降低了31.2%,在12个月后降低了20.8%。入选患者对产品的耐受性良好,并且没有脱落。结论:唾液链球菌24SMB和口腔链球菌89a的预防性细菌治疗对复发性上呼吸道感染史的儿童可以减少耳鼻喉科感染的发作次数。由于寻找新的有效抗生素化合物的难度越来越大,细菌疗法在临床上甚至可能更加重要。与抗生素相比,必须找到新的替代治疗方法,对患者的天然有益菌群具有更高的特异性和安全性;缺乏药物相互作用;利用互补的系统性作用方式的能力;并大大降低了患者群体和环境中产生抗药性的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号